BioSpace News Archive

Bio NC

Crown Bioscience Releases Scientific Posters Detailing Innovations in Preclinical Cancer Pharmacology

Crown Bioscience presented more than a dozen scientific posters describing innovations in the field of preclinical cancer research at AACR-NCI-EORTC 2017.

December 8, 2017
·
2 min read
BIOCAD Demonstrated the Use of Hela Cells in Oncology Research

BioCad demonstrated how “immortal” HeLa cells are used all over the world in oncology research and in development of anti-cancer drugs.

December 8, 2017
·
2 min read
Drug Development

Flexion Therapeutics Enrolls First Patient in Phase II Pharmacokinetics and Safety Study of ZILRETTA (Triamcinolone Acetonide Extended-Release Injectable Suspension) in Bilateral Osteoarthritis of the Knee

The randomized, open-label, Phase 2 study is expected to enroll approximately 24 patients.

December 8, 2017
·
6 min read
BioMidwest

Skyline Medical Issues Letter to Shareholders

The company laid out some of the plans Skyline’s management team has been working toward over the past several months.

December 8, 2017
·
10 min read
Business

Medline, ROi Announce Two New Agreements on Traditional Wound Care and Incontinence Products

The three-year collaboration will take effect on Feb. 1, 2018.

December 8, 2017
·
2 min read
Drug Development

Trovagene Presents Data Showing Sensitivity of Triple Negative Breast Cancer (TNBC) Cell Lines to PCM-075 and Synergy with Zytiga® at San Antonio Breast Cancer Symposium (SABCS)

The presentation data indicates that PCM-075 in combination with anti-androgen, abiraterone acetate are synergistic in inducing cell death within an AR+ TNBC cell line.

December 8, 2017
·
6 min read
Drug Development

Lilly’s Cyramza Fails to Improve Overall Survival in Phase III Gastric Cancer Study

The trial met its primary endpoint of progression-free survival but did not improve overall survival, a secondary endpoint.

December 8, 2017
·
22 min read
Biotech Bay

Rigel Pharma Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Rigel today announced that on December 4, 2017 the Compensation Committee of Rigel’s Board of Directors approved the grant of inducement stock options to purchase an aggregate of 60,000 shares of common stock to one new employee.

December 8, 2017
·
2 min read